HIV / AIDS

Investigators detected HIV DNA in the cerebrospinal fluid of 48% of participants, which was linked to worse neurocognitive outcomes.

The guidelines include a new section featuring recommendations for treating transgender people living with HIV.

Mosaico plans to register 3800 HIV-negative participants aged 18 to 60 years when enrollment opens later this year.

Long-acting reservoir-style PrEP implants could help solve adherence issues.

PrEP awareness among these MSM rose from 60% to 90% from 2014 to 2017, and PrEP use increased from 6% to 35%.

New research assesses potential alternatives to a daily dose of emtricitabine/tenofovir. It finds mixed results.

The program combines PrEP administration along with evidence-based behavioral intervention to reduce HIV risk behavior for HIV-negative, opioid-dependent people who use drugs and are receiving treatment.

Identifying patients in electronic health records databases who would benefit from taking PrEP is much easier with the advent of an automated algorithm.

The phase 3 study is assessing whether a switch to dolutegravir plus lamivudine from TAF-containing HIV treatment regimens can successfully maintain viral suppression.

Investigators sought to identify potentially intervenable factors that affect mortality among PLWH in the city of San Francisco.

The investigators used a combined approach of LASER ART and CRISPR-Cas9 to successfully eliminate replication-competent HIV-1 DNA from the genome of living mice.

The FDA approved the first darunavir-based single-tablet regimen for the treatment of HIV in July 2018. How is it working out for patients and providers alike?

Testing and information will be available at select Walgreens stores in more than 260 cities on National HIV Testing Day on Thursday between 10 am and 7 pm.

The recommendation means more patients will be able to access PrEP at no cost. However, it likely won’t be enough to dramatically boost PrEP usage without other systemic advances.

The FDA has expanded the patient population and issued updated drug interactions, warnings, and precautions for Biktarvy.

A recent animal trial reveals that MK-8591 offers protection against SHIV at lower and more infrequent doses than current PrEP options, renewing hope for more choices in the future.

Experts provide community physicians treating HIV with practical advice for screening, diagnosing, and managing patients with HIV.

A phase 1 study demonstrated that pembrolizumab is appropriate for FDA-approved indications and clinical trials among people living with HIV and advanced cancer.

According to the study, the 3 contraceptive methods that were studied had high levels of safety and effectiveness in preventing pregnancy and well received by study participants.

A recent study found some improvement in bone density after PrEP discontinuation along with some lingering concerns, particularly among the youngest participants.

Although a new study finds that bone toxicities were lower than expected in PrEP users, investigators say that those at higher risk of bone fracture may want to seek PrEP alternatives once available.

A new study combines models on PrEP use in both adult MSM as well as adolescent sexual minority males.

Meeting goals to eliminate HIV, viral hepatitis, and sexually transmitted infections by 2030 will require accelerated efforts, according to a progress report from the WHO.

Very early introduction of ART may alter HIV immune response long term, with implications for development of effective vaccine.

Nearly 500 children are infected with HIV after being put at risk due to poor medical practices in a country where violence against individuals living with HIV is still an issue.

A look at up-and-coming HIV drugs in development.

Following the launch of the campaign in March 2015, investigators saw a 77% increase in HIV testing compared with January and February of the same year in Beijing.

For the first time, patients with new HIV diagnoses have a 2-drug regimen option.

The likelihood of using PrEP is significantly influenced by recommendations from health care providers and concerns about side effects, according to a recent study of heterosexual individuals in Philadelphia.

The LATITUDE study will assess whether long-acting injectable cabotegravir/rilpivirine is superior to oral ART in managing HIV infections among this population.